10x Genomics revenue and financials
$80.66Change from previous close: −17.47%Absolute change: −$17.08
In the fiscal year ended December 2025, 10x Genomics reported revenue of $642.82M (+5.25% year over year). The net loss was $43.54M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +5.25%
- 2025 vs 2024
- Net margin
- -6.8%
- 2024: -29.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 17.0 | 26.1 | 40.8 | 43.2 | 17.7 | 34.4 | -6.7 | 21.6 | 7.5 | -15.7 | 25.8 | -25.3 |
| Depreciation and amortization | 9.7 | 10.0 | 12.1 | 12.3 | 7.8 | 8.0 | 10.6 | 10.8 | 10.9 | 11.5 | 11.7 | 11.4 |
| Capital expenditure | -1.6 | -1.6 | -1.8 | -0.7 | -1.6 | -1.9 | -2.7 | -3.9 | -2.9 | -2.9 | -3.5 | -15.2 |
| Investing cash flow | -7.7 | -1.3 | -1.8 | -8.8 | -0.9 | -1.9 | -51.6 | -3.6 | 11.9 | 10.6 | 13.1 | 4.9 |
| Financing cash flow | 3.0 | -8.4 | 2.2 | 0.6 | 3.5 | 0.4 | 4.5 | 0.2 | 4.6 | 1.6 | 5.6 | 4.4 |
| Effect of exchange rates | -0.0 | -0.1 | 0.0 | -0.0 | 0.4 | 0.1 | -0.3 | 0.2 | -0.0 | -0.0 | 0.1 | -0.1 |
| Net change in cash | 12.2 | 16.3 | 41.3 | 35.0 | 20.7 | 33.0 | -54.1 | 18.3 | 24.0 | -3.5 | 44.5 | -16.1 |
| Free cash flow | 15.4 | 24.5 | 39.0 | 42.5 | 16.1 | 32.5 | -9.5 | 17.8 | 4.6 | -18.6 | 22.3 | -40.5 |
| Levered free cash flow | 30.8 | 11.3 | 48.2 | 82.0 | -24.6 | 35.1 | 11.2 | 29.8 | 18.2 | 1.6 | 45.1 | -5.1 |